<?xml version='1.0' encoding='utf-8'?>
<document id="22899355"><sentence text="Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam."><entity charOffset="82-90" id="DDI-PubMed.22899355.s1.e0" text="morphine" /><entity charOffset="91-98" id="DDI-PubMed.22899355.s1.e1" text="codeine" /><entity charOffset="103-111" id="DDI-PubMed.22899355.s1.e2" text="diazepam" /><pair ddi="false" e1="DDI-PubMed.22899355.s1.e0" e2="DDI-PubMed.22899355.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22899355.s1.e0" e2="DDI-PubMed.22899355.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22899355.s1.e0" e2="DDI-PubMed.22899355.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22899355.s1.e1" e2="DDI-PubMed.22899355.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22899355.s1.e1" e2="DDI-PubMed.22899355.s1.e2" /></sentence><sentence text="Genetic polymorphisms in cytochrome P 450 (CYP) enzymes could lead to a phenotype with altered enzyme activity" /><sentence text=" In pharmacotherapy, genotype-based dose recommendations achieved great importance for several drugs" /><sentence text=" In our pilot study, we ask if these genetic tests should be applied to forensic problems as a matter of routine" /><sentence text=" Starting from 2004 through 2008, we screened routine cases for samples where the relation of parent compound to metabolite(s) (P/M ratio), particularly morphine to codeine ratios and diazepam to its metabolites, was noticeable or not consistent with the information provided by the defendants"><entity charOffset="153-161" id="DDI-PubMed.22899355.s5.e0" text="morphine" /><entity charOffset="165-172" id="DDI-PubMed.22899355.s5.e1" text="codeine" /><entity charOffset="184-192" id="DDI-PubMed.22899355.s5.e2" text="diazepam" /><pair ddi="false" e1="DDI-PubMed.22899355.s5.e0" e2="DDI-PubMed.22899355.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22899355.s5.e0" e2="DDI-PubMed.22899355.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22899355.s5.e0" e2="DDI-PubMed.22899355.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22899355.s5.e1" e2="DDI-PubMed.22899355.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22899355.s5.e1" e2="DDI-PubMed.22899355.s5.e2" /></sentence><sentence text=" We found 11 samples with conspicuous results" /><sentence text=" These were analyzed for polymorphisms of the CYP 2D6 and 2C19 genes using the Roche AmpliChip Cytochrome P450 Genotyping test" /><sentence text=" If not previously conducted, a general unknown analysis by gas chromatography/mass spectrometry (GC/MS) was additionally carried out" /><sentence text=" For CYP 2D6, we found two cases with the genotype poor metabolizer (PM), three cases with heterozygote extensive metabolizer genotype classified as an intermediate metabolizer (IM) with probably reduced enzyme activities, but no ultrarapid metabolizer genotype" /><sentence text=" For CYP 2C19, two cases were characterized as IM phenotypes, with no PM found" /><sentence text=" Once we achieved no appropriate amounts of DNA, one case was excluded after GC/MS analysis" /><sentence text=" Only in one case could the polymorphism clearly explain the changes in drug metabolism" /><sentence text=" More frequently, a drug-drug interaction was thought to have a stronger impact" /><sentence text=" Additionally, our results suggest that IM genotypes may be more relevant than previously suspected" /><sentence text=" With respect to the small number of cases in which we thought a genotyping would be helpful, we conclude that the overall relevance of toxicogenetics in forensic problems is moderate" /><sentence text=" However, in some individual cases, a genotyping may provide new insight" /><sentence text="" /></document>